[1]
|
Chalasani, N., Younossi, Z., Lavine, J.E., et al. (2018) The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 67, 328-357.
https://doi.org/10.1002/hep.29367
|
[2]
|
Younossi, Z.M., Golabi, P., Paik, J.M., et al. (2023) The Global Epidemi-ology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review. Hepatology, 77, 1335-1347.
https://doi.org/10.1097/HEP.0000000000000004
|
[3]
|
Wang, X.J. and Malhi, H. (2018) Nonalcoholic Fatty Liver Disease. Annals of Internal Medicine, 169, Itc65-itc80.
https://doi.org/10.7326/IsTranslatedFrom_AITC201811060_Japanese
|
[4]
|
Quek, J., Chan, K.E., Wong, Z.Y., et al. (2023) Global Prevalence of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in the Overweight and Obese Population: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 8, 20-30. https://doi.org/10.1016/S2468-1253(22)00317-X
|
[5]
|
Younossi, Z.M., Golabi, P., De Avila, L., et al. (2019) The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Journal of Hepatology, 71, 793-801.
https://doi.org/10.1016/j.jhep.2019.06.021
|
[6]
|
北京高血压防治协会, 北京糖尿病防治协会, 北京慢性病防治与健康教育研究会, 等. 基层心血管病综合管理实践指南2020[J]. 中国医学前沿杂志(电子版), 2020, 12(8): 前插1, 1-73.
|
[7]
|
Sinn, D.H., Kang, D., Chang, Y., et al. (2020) Non-Alcoholic Fatty Liver Disease and the Incidence of Myocardial Infarction: A Cohort Study. Journal of Gastroenterology and Hepatology, 35, 833-839.
https://doi.org/10.1111/jgh.14856
|
[8]
|
Mahmood, S.S., Levy, D., Vasan, R.S., et al. (2014) The Framingham Heart Study and the Epidemiology of Cardiovascular Disease: A Historical Perspective. The Lancet, 383, 999-1008.
https://doi.org/10.1016/S0140-6736(13)61752-3
|
[9]
|
Tomah, S., Alkhouri, N. and Hamdy, O. (2020) Nonalco-holic Fatty Liver Disease and Type 2 Diabetes: Where Do Diabetologists Stand? Clinical Diabetes and Endocrinology, 6, Article No. 9.
https://doi.org/10.1186/s40842-020-00097-1
|
[10]
|
Zhang, M., Deng, Q., Wang, L., et al. (2018) Prevalence of Dyslipidemia and Achievement of Low-Density Lipoprotein Cholesterol Targets in Chinese Adults: A Nationally Repre-sentative Survey of 163,641 Adults. International Journal of Cardiology, 260, 196-203. https://doi.org/10.1016/j.ijcard.2017.12.069
|
[11]
|
Hsiao, C.-C., Teng, P.-H., Wu, Y.-J., et al. (2021) Severe, but Not Mild to Moderate, Non-Alcoholic Fatty Liver Disease Associated with Increased Risk of Subclinical Coronary Ath-erosclerosis. BMC Cardiovascular Disorders, 21, Article No. 244. https://doi.org/10.1186/s12872-021-02060-z
|
[12]
|
Mcnally, B.B., Rangan, P., Wijarnpreecha, K., et al. (2023) Fi-brosis-4 Index Score Predicts Concomitant Coronary Artery Diseases across the Spectrum of Fatty Liver Disease. Diges-tive Diseases and Sciences, 68, 3765-3773.
https://doi.org/10.1007/s10620-023-07987-1
|
[13]
|
Mantovani, A., Csermely, A., Petracca, G., et al. (2021) Non-Alcoholic Fatty Liver Disease and Risk of Fatal and Non-Fatal Cardiovascular Events: An Updated Systematic Re-view and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 6, 903-913. https://doi.org/10.1016/S2468-1253(21)00308-3
|
[14]
|
Yu, M.M., Tang, X.L., Zhao, X., et al. (2022) Plaque Pro-gression at Coronary CT Angiography Links Non-Alcoholic Fatty Liver Disease and Cardiovascular Events: A Prospec-tive Single-Center Study. European Radiology, 32, 8111-8121. https://doi.org/10.1007/s00330-022-08904-2
|
[15]
|
Loomba, R., Friedman, S.L. and Shulman, G.I. (2021) Mecha-nisms and Disease Consequences of Nonalcoholic Fatty Liver Disease. Cell, 184, 2537-2564. https://doi.org/10.1016/j.cell.2021.04.015
|
[16]
|
Anstee, Q.M., Mantovani, A., Tilg, H., et al. (2018) Risk of Car-diomyopathy and Cardiac Arrhythmias in Patients with Nonalcoholic Fatty Liver Disease. Nature Reviews Gastroenter-ology & Hepatology, 15, 425-439.
https://doi.org/10.1038/s41575-018-0010-0
|
[17]
|
Duan, Y., Pan, X., Luo, J., et al. (2022) Association of Inflam-matory Cytokines with Non-Alcoholic Fatty Liver Disease. Frontiers in Immunology, 13, Article ID: 880298. https://doi.org/10.3389/fimmu.2022.880298
|
[18]
|
Xiong, J., Chen, X., Zhao, Z., et al. (2022) A Potential Link be-tween Plasma Short-Chain Fatty Acids, TNF-α Level and Disease Progression in Non-Alcoholic Fatty Liver Disease: A Retrospective Study. Experimental and Therapeutic Medicine, 24, Article No. 598. https://doi.org/10.3892/etm.2022.11536
|
[19]
|
Fricker, Z.P., Pedley, A., Massaro, J.M., et al. (2019) Liver Fat Is Associated with Markers of Inflammation and Oxidative Stress in Analysis of Data from the Framingham Heart Study. Clinical Gastroenterology and Hepatology, 17, 1157-1164.e4. https://doi.org/10.1016/j.cgh.2018.11.037
|
[20]
|
Kaptoge, S., Di Angelantonio, E., Pennells, L., et al. (2012) C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. The New England Journal of Medicine, 367, 1310-1320. https://doi.org/10.1056/NEJMoa1107477
|
[21]
|
Tang, W.H.W., Bäckhed, F., Landmesser, U., et al. (2019) Intestinal Microbiota in Cardiovascular Health and Disease: JACC State-of-the-Art Review. Journal of the Amer-ican College of Cardiology, 73, 2089-2105.
https://doi.org/10.1016/j.jacc.2019.03.024
|
[22]
|
Duewell, P., Kono, H., Rayner, K.J., et al. (2010) NLRP3 Inflam-masomes Are Required for Atherogenesis and Activated by Cholesterol Crystals. Nature, 464, 1357-1361. https://doi.org/10.1038/nature08938
|
[23]
|
Bäck, M., Yurdagul, A., Tabas, I., et al. (2019) Inflammation and Its Resolution in Atherosclerosis: Mediators and Therapeutic Opportunities. Nature Reviews Cardiology, 16, 389-406. https://doi.org/10.1038/s41569-019-0169-2
|
[24]
|
Petta, S., Argano, C., Colomba, D., et al. (2015) Epicardial Fat, Cardiac Geometry and Cardiac Function in Patients with Non-Alcoholic Fatty Liver Disease: Association with the Sever-ity of Liver Disease. Journal of Hepatology, 62, 928-933. https://doi.org/10.1016/j.jhep.2014.11.030
|
[25]
|
Liu, B., Li, Y., Li, Y., et al. (2019) Association of Epicardial Adipose Tissue with Non-Alcoholic Fatty Liver Disease: A Me-ta-Analysis. Hepatology International, 13, 757-765. https://doi.org/10.1007/s12072-019-09972-1
|
[26]
|
Packer, M. (2018) Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. Journal of the American College of Cardiology, 71, 2360-2372.
https://doi.org/10.1016/j.jacc.2018.03.509
|
[27]
|
Madonna, R., Massaro, M., Scoditti, E., et al. (2019) The Epicardial Adipose Tissue and the Coronary Arteries: Dangerous Liaisons. Cardiovascular Research, 115, 1013-1025. https://doi.org/10.1093/cvr/cvz062
|
[28]
|
Grunwald, S.A., Haafke, S., Grieben, U., et al. (2022) Statins Aggravate the Risk of Insulin Resistance in Human Muscle. International Journal of Molecular Sciences, 23, Article No. 2398. https://doi.org/10.3390/ijms23042398
|
[29]
|
Flannery, C., Dufour, S., Rabøl, R., et al. (2012) Skeletal Muscle Insu-lin Resistance Promotes Increased Hepatic de Novo Lipogenesis, Hyperlipidemia, and Hepatic Steatosis in the Elderly. Diabetes, 61, 2711-2717.
https://doi.org/10.2337/db12-0206
|
[30]
|
Ke, Z., Huang, R., Xu, X., et al. (2023) Long-Term High Level of Insulin Resistance Is Associated with an Increased Prevalence of Coronary Artery Calcification: The CARDIA Study. Journal of the American Heart Association, 12, e028985. https://doi.org/10.1161/JAHA.122.028985
|
[31]
|
Martín-Saladich, Q., Simó, R., Aguadé-Bruix, S., et al. (2023) Insights into Insulin Resistance and Calcification in the Myocardium in Type 2 Diabetes: A Coronary Artery Analysis. International Journal of Molecular Sciences, 24, Article No. 3250. https://doi.org/10.3390/ijms24043250
|
[32]
|
Di Pino, A. and Defronzo, R.A. (2019) Insulin Resistance and Athero-sclerosis: Implications for Insulin-Sensitizing Agents. Endocrine Reviews, 40, 1447-1467. https://doi.org/10.1210/er.2018-00141
|
[33]
|
Cimmino, G., Muscoli, S., De Rosa, S., et al. (2023) Evolving Con-cepts in the Pathophysiology of Atherosclerosis: From Endothelial Dysfunction to Thrombus Formation through Multiple Shades of Inflammation. Journal of Cardiovascular Medicine (Hagerstown), 24, e156-e167. https://doi.org/10.2459/JCM.0000000000001450
|
[34]
|
Francque, S.M., Van Der Graaff, D. and Kwanten, W.J. (2016) Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk: Pathophysiological Mechanisms and Implications. Journal of Hepatology, 65, 425-443.
https://doi.org/10.1016/j.jhep.2016.04.005
|
[35]
|
Stahl, E.P., Dhindsa, D.S., Lee, S.K., et al. (2019) Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 73, 948-963. https://doi.org/10.1016/j.jacc.2018.11.050
|
[36]
|
Vita, T., Murphy, D.J., Osborne, M.T., et al. (2019) As-sociation between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Per-fusion PET/CT. Radiology, 291, 330-337.
https://doi.org/10.1148/radiol.2019181793
|
[37]
|
Xiang, W., Yang, Y., Weng, L., et al. (2023) Hyperhomocyste-inemia Activates NLRP3 Inflammasome to Cause Hepatic Steatosis and Insulin Resistance via MDM2-Mediated Ubiqui-tination of HSF1. International Immunopharmacology, 118, Article ID: 110085. https://doi.org/10.1016/j.intimp.2023.110085
|
[38]
|
Fu, L., Wang, Y. and Hu, Y.Q. (2023) Association between Homocysteine and Nonalcoholic Fatty Liver Disease: Mendelian Randomisation Study. European Journal of Clinical Investigation, 53, e13895.
https://doi.org/10.1111/eci.13895
|
[39]
|
Gao, Y., Guo, Y., Hao, W., et al. (2023) Correlation Analysis and Diagnos-tic Value of Serum Homocysteine, Cystatin C and Uric Acid Levels with the Severity of Coronary Artery Stenosis in Pa-tients with Coronary Heart Disease. International Journal of General Medicine, 16, 2719-2731. https://doi.org/10.2147/IJGM.S411417
|
[40]
|
Sharpton, S.R., Ajmera, V. and Loomba, R. (2019) Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clinical Gastroenterology and Hepatology 17, 296-306.
https://doi.org/10.1016/j.cgh.2018.08.065
|
[41]
|
Loomba, R., Seguritan, V., Li, W., et al. (2017) Gut Microbi-ome-Based Metagenomic Signature for Non-Invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metabolism, 25, 1054-1062.e5.
https://doi.org/10.1016/j.cmet.2017.04.001
|
[42]
|
Jie, Z., Xia, H., Zhong, S.L., et al. (2017) The Gut Microbiome in Atherosclerotic Cardiovascular Disease. Nature Communications, 8, Article No. 845. https://doi.org/10.1038/s41467-017-00900-1
|
[43]
|
Shen, F., Zheng, R.D., Sun, X.Q., et al. (2017) Gut Microbiota Dysbiosis in Patients with Non-Alcoholic Fatty Liver Disease. Hepatobiliary & Pancreatic Diseases International, 16, 375-381.
https://doi.org/10.1016/S1499-3872(17)60019-5
|
[44]
|
Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., et al. (2020) Gut Microbiota and Human NAFLD: Disentangling Microbial Signatures from Metabolic Disorders. Nature Reviews Gastroenterology & Hepatology, 17, 279-297.
https://doi.org/10.1038/s41575-020-0269-9
|
[45]
|
Nian, F., Zhu, C., Jin, N., et al. (2023) Gut Microbiota Metabolite TMAO Promoted Lipid Deposition and Fibrosis Process via KRT17 in Fatty Liver Cells in Vitro. Biochemical and Bio-physical Research Communications, 669, 134-142. https://doi.org/10.1016/j.bbrc.2023.05.041
|